Category: St. Jude Medical
St. Jude Medical CEO Daniel Starks says the FDA's warnings of manufacturing deficiencies at a California plant are unrelated to the safety and reliability of the Durata defibrillator leads that are made there.
St. Jude Medical's (NYSE:STJ) implanted cardiac device market share is in great shape despite ongoing issues with its high-voltage defibrillator leads, CEO Daniel Starks told an audience at the J.P. Morgan healthcare conference last night.
St. Jude Medical admits to quality control problems at the plant that makes its Durata defibrillator leads in a letter to the FDA reviewed by the Wall Street Journal and says it's putting procedures in place to remedy the issues.
St. Jude Medical (NYSE:STJ) copped to quality control problems at the Sylmar, Calif., plant that makes its next-generation Durata defibrillator leads, saying it's put measures in place to remedy the issues.
Boston Scientific CFO Jeffrey Capello says the medical device giant is looking to capitalize on the reliability of its ICD leads, especially in light of the "challenges" faced by an ICD competitor.
Boston Scientific (NYSE:BSX) is looking for ways to leverage its product pipeline in 2013, part of which may include capitalizing on some of the "challenges" facing one of their biggest rivals.
MassDevice.com looks at the internet chatter surrounding the medical device industry with some of most searched-for companies of 2012.
The medical device industry was full of big stories in 2012, ranging from efforts to bring down the device tax and related layoffs to epic public face-offs between industry leaders.
St. Jude and AorTech International come to a manufacture and supply agreement after St. Jude wins an injunction preventing termination of their contract.
Noted cardiologist and frequent medtech critic Dr. Robert Hauser warns that doctors need more data on the safety and effectiveness before widely accepting Boston Scientific's newly acquired and FDA approved lead-free implantable defibrillator.
Frequent medtech challenger Dr. Robert Hauser offered some words of warning for physicians clamoring over Boston Scientific's (NYSE:BSX) wire-free implantable defibrillator: curb your enthusiasm.
Medical devices made a lot of headlines in 2012, and the word "layoffs" was in many of them.
The medical device industry had a lot of big stories during the last year, including tales of recalls, lawsuits and CEO swapping, but the single factor that drove more big headlines than any other was news of layoffs.
Some of the biggest companies in the industry announced significant cuts in 2012, amounting to about 7,000 reported layoffs, by some estimates.